About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

NCT00610714·50 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AstraZeneca

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Have a diagnosis of advanced ovarian cancer
Have evidence of recurrence or disease progression at least 6 months following treatment cessation of 1st or 2nd line platinum containing therapy
Estimated life expectancy of more than 12 weeks

You may not be if

Central Nervous System (CNS) metastases
Received more than 2 prior chemotherapy regimens for ovarian cancer treatment
Inadequate bone marrow reserve
Inadequate liver function, renal function or low haemoglobin
Pregnant, breastfeeding or if of child-bearing status unwilling to use an acceptable method of contraception

The record

StatusCompleted

PhasePhase 2

Taking part211

StartedApr 2008

UpdatedDec 18, 2012

Conditions

Ovarian Neoplasms Ovarian Cancer

Where50

Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria